Molecular Pathology of Cancer Group
Search for publications
Only original articles, editorials, guidelines.
-
Madariaga A, Cots M, Hierro C, Robles C, Garrido S, Barretina-Ginesta MP, Serrano A, Serena M, Salcedo P, Mariátegui N, Guerra E.
Needs and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain
CLINICAL & TRANSLATIONAL ONCOLOGY . : .
-
Lopez-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjón A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de Los Rios V, Redondo A, Pelaez-Garcia A, Hardisson D.
The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas
Cells . 14(21): .
-
Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull-Delgado A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer-Montiel A.
A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study
CLINICAL & TRANSLATIONAL ONCOLOGY . 28(3): 1040-1048.
-
Soria A, Díaz A, Iruzubieta P, Martín-Mateos R, Salcedo-Allende MT, Jiménez-Masip A, Fuster-Anglada C, Arias-Loste MT, Perna C, El Maimouni C, Pericas JM, Ferrer-Gómez A, González CJ, Muñoz-Martínez S, Padilla M, Crespo J, Calixto Z, Sabiote C, Albillos A, Cervera M, Olivas I, Arvaniti P, Hernández-Évole H, Jiménez-Esquivel N, Gratacós-Ginès J, Juanola A, Pose E, Coll M, Nadal R, Pérez-Guasch M, Fabrellas N, Ginès P, Londoño MC, Graupera I.
Autoantibodies are associated with worse outcomes in MASLD
JHEP REPORTS . 7(10): 101470-101470.
-
Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.
Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer
LABORATORY INVESTIGATION . 105(10): 104199-104199.
-
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A.
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation
JOURNAL OF CLINICAL ONCOLOGY . 43(26): 2908-2917. Number of citations: 2
-
Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society . : 102654-102654.
-
Quindós-Varela M, Soto de Prado-Otero D, Gallego A, García Y, Guerra E, Estévez-García P, Barretina-Ginesta MP, Borraz P, González-Martín A, Rubio MJ.
Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study
Oncology and therapy . 13(3): 631-648.
-
Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M.
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
European Urology Focus . 11(5): 736-746.
-
Manso L, Sánchez-Bayona R, Guerra JA, Cortés-Salgado A, Cejalvo JM, Garcia-Saenz JA, Morales S, González-Cortijo L, Mourón S, Bueno MJ, Garma LD, Quintela-Fandino M.
A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Cancer Research Communications . 5(9): 1728-1737.
-
Aguzzi C, De Summa S, Molina-Cerrillo J, Alonso-Gordoa T, Nabissi M, Rizzo M, Zeppellini A, Sunela K, Sorgentoni G, Ortega C, Massari F, Marques Monteiro FS, Battelli N, Porta C, Santoni G, Santoni M.
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a)
Biochemistry and Biophysics Reports . 43: 102162-102162.
-
López-Miranda E, Pérez-García JM, Gión M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, García MM, González-Santiago S, Bermejo B, Morales S, Carañana V, Garrigós L, Fernández-Pinto M, García-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcalá-López D, Llombart-Cussac A, Cortés J.
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
BREAST CANCER RESEARCH . 27(1): 141-141.
-
Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA.
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma? Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study
Archives of pathology & laboratory medicine . 149(8): 741-750. Number of citations: 2
-
Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A.
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
NATURE MEDICINE . 31(8): 2746-2754. Number of citations: 8
-
Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, Couñago F, Sanmamed N, Domínguez Esteban M, López Valcárcel M, Manneh R, Borque-Fernando Á, Sala González N, Maroto P.
Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.
Oncology Reviews . 19: 1599292-1599292.
-
Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M.
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Frontiers in Oncology . 15: 1605282-1605282. Number of citations: 1
-
Manneh R, Molina-Cerrillo J, de Velasco G, Ibatá L, Martínez S, Ruiz-Granados Á, Alonso-Gordoa T.
PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis
PHARMACEUTICALS . 18(7): .
-
Gorospe L, Saavedra-Serrano C, Martínez-Jáñez N.
Eribulin-induced pulmonary toxicity mimicking metastatic lung disease.
MEDICINA CLINICA . 165(1): 106993-106993.